CRESCITA THERAPEUTICS INC (CTX.CA) Stock Fundamental Analysis
Canada - TSX:CTX - CA2258471028 - Common Stock
0.455 CAD
-0.01 (-1.09%)
Overall CTX gets a fundamental rating of 2 out of 10. We evaluated CTX against 32 industry peers in the Pharmaceuticals industry. The financial health of CTX is average, but there are quite some concerns on its profitability. CTX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
CTX had negative earnings in the past year.
In the past year CTX had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: CTX reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: CTX reported negative operating cash flow in multiple years.
1.2 Ratios
With a Return On Assets value of -6.09%, CTX perfoms like the industry average, outperforming 53.13% of the companies in the same industry.
CTX's Return On Equity of -8.53% is in line compared to the rest of the industry. CTX outperforms 59.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.09% | ||
| ROE | -8.53% | ||
| ROIC | N/A |
ROA(3y)-5.89%
ROA(5y)-4.27%
ROE(3y)-7.95%
ROE(5y)-5.81%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 51.98%, CTX is doing good in the industry, outperforming 78.13% of the companies in the same industry.
In the last couple of years the Gross Margin of CTX has declined.
CTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 51.98% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.3%
GM growth 5Y-7.9%
2. Health
2.1 Basic Checks
CTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CTX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for CTX has been reduced compared to 5 years ago.
CTX has a better debt/assets ratio than last year.
2.2 Solvency
CTX has an Altman-Z score of -0.94. This is a bad value and indicates that CTX is not financially healthy and even has some risk of bankruptcy.
CTX's Altman-Z score of -0.94 is in line compared to the rest of the industry. CTX outperforms 46.88% of its industry peers.
CTX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.01, CTX belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.94 |
ROIC/WACCN/A
WACC7.77%
2.3 Liquidity
CTX has a Current Ratio of 2.60. This indicates that CTX is financially healthy and has no problem in meeting its short term obligations.
CTX's Current ratio of 2.60 is fine compared to the rest of the industry. CTX outperforms 68.75% of its industry peers.
A Quick Ratio of 1.78 indicates that CTX should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.78, CTX is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.6 | ||
| Quick Ratio | 1.78 |
3. Growth
3.1 Past
CTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.82%, which is quite impressive.
Looking at the last year, CTX shows a very strong growth in Revenue. The Revenue has grown by 20.35%.
The Revenue has been decreasing by -2.60% on average over the past years.
EPS 1Y (TTM)52.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%188.03%
Revenue 1Y (TTM)20.35%
Revenue growth 3Y5.3%
Revenue growth 5Y-2.6%
Sales Q2Q%52.47%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CTX. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:CTX (11/17/2025, 7:00:00 PM)
0.455
-0.01 (-1.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners12.78%
Ins Owner ChangeN/A
Market Cap8.58M
Revenue(TTM)20.27M
Net Income(TTM)-1.33M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.42 | ||
| P/FCF | N/A | ||
| P/OCF | 6.68 | ||
| P/B | 0.55 | ||
| P/tB | 0.61 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.07
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.07
OCFY14.97%
SpS1.08
BVpS0.83
TBVpS0.75
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.09% | ||
| ROE | -8.53% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 51.98% | ||
| FCFM | N/A |
ROA(3y)-5.89%
ROA(5y)-4.27%
ROE(3y)-7.95%
ROE(5y)-5.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.3%
GM growth 5Y-7.9%
F-Score6
Asset Turnover0.93
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.6 | ||
| Quick Ratio | 1.78 | ||
| Altman-Z | -0.94 |
F-Score6
WACC7.77%
ROIC/WACCN/A
Cap/Depr(3y)37.08%
Cap/Depr(5y)28.12%
Cap/Sales(3y)2.6%
Cap/Sales(5y)2.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%188.03%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)20.35%
Revenue growth 3Y5.3%
Revenue growth 5Y-2.6%
Sales Q2Q%52.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y40.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-131.86%
FCF growth 3YN/A
FCF growth 5Y-21.27%
OCF growth 1Y185.33%
OCF growth 3YN/A
OCF growth 5Y-12.49%
CRESCITA THERAPEUTICS INC / CTX.CA FAQ
What is the ChartMill fundamental rating of CRESCITA THERAPEUTICS INC (CTX.CA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to CTX.CA.
Can you provide the valuation status for CRESCITA THERAPEUTICS INC?
ChartMill assigns a valuation rating of 0 / 10 to CRESCITA THERAPEUTICS INC (CTX.CA). This can be considered as Overvalued.
How profitable is CRESCITA THERAPEUTICS INC (CTX.CA) stock?
CRESCITA THERAPEUTICS INC (CTX.CA) has a profitability rating of 2 / 10.